Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceSTU:0ME -0.27%70 3-1 Month Momentum % is 31.54% as of Sep. 03, 2026. GuruFocus rates STU:0ME with a GF Score™ of 70/100 and a GF Value™ of €45.69 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Twist Bioscience ranks better than 92.89% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-03), Twist Bioscience's 3-1 Month Momentum % is 31.54%.
The industry rank for Twist Bioscience's 3-1 Month Momentum % or its related term are showing as below:
STU:0ME's 3-1 Month Momentum % is ranked better than 92.89% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.9
vs STU:0ME: 31.54
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Twist Bioscience 3-1 Month Momentum % Related Terms
STU:0ME vs QGEN, RDNT, SHC: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (STU:0ME) has a 3-1 Month Momentum % of 31.54% as of Sep. 03, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Twist Bioscience and its competitors. According to the industry distribution chart, Twist Bioscience ranks #15 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 7.1%.
Is Twist Bioscience's 3-1 Month Momentum % too high?
Twist Bioscience's current 3-1 Month Momentum % is 31.54%. Based on the distribution chart, Twist Bioscience ranks #15 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Twist Bioscience has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's 3-1 Month Momentum % compare to QGEN and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #15 out of 211 companies for 3-1 Month Momentum %. This places Twist Bioscience in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Twist Bioscience and its competitors. Twist Bioscience's current 3-1 Month Momentum % is 31.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (STU:0ME) is currently considered Significantly Overvalued. The stock's GF Value™ is €45.69, compared to a current price of €112.90 — trading 147.1% above its estimated fair value. The current 3-1 Month Momentum % is 31.54%. Twist Bioscience's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Twist Bioscience (STU:0ME), the current 3-1 Month Momentum % is 31.54% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (STU:0ME) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of €112.90 is trading 147.1% above its estimated GF Value™ of €45.69.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for STU:0ME:
3-1 Month Momentum %: 31.54%
GF Value™: €45.69 vs. price of €112.90 (147.1% above fair value)
No single metric tells the full story. See the STU:0ME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
70GF Score
Get the complete analysis for STU:0ME
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0ME has been successfully added to your 
